Turkovac
Vaccine description | |
---|---|
Target | SARS-CoV-2 |
Vaccine type | Inactivated |
Clinical data | |
Other names | ERUCOV-VAC |
Routes of administration | Intramuscular |
Legal status | |
Legal status |
Part of a series on the |
COVID-19 pandemic |
---|
|
2019 2020
2021
2022 |
International response
|
Medical response |
By country
|
Impacts
|
COVID-19 portal |
Turkovac[1] (pronunciation: ['tɜ:rkəvæk]) (temporarily named as ERUCOV-VAC[2]) is a COVID-19 vaccine developed by Health Institutes of Turkey and Erciyes University.
Clinical trials
In November 2020, TURKOVAC started on phase I trials with 44 participants in Turkey.[3]
In February 2021, TURKOVAC started on phase II trials with 250 participants in Turkey.[4]
In June 2021, TURKOVAC started on phase III trials with 40,800 participants in Turkey.[5]
Authorization
On 25 November 2021, the Turkish Minister of Health reported that Turkovac's application for emergency use authorization had been filed.[6] On 22 December, Turkish President Recep Tayyip Erdogan announced the emergency use approval of Turkovac.[7]
References
- ↑ Cakmak BN (22 June 2021). "Turkey names home-grown COVID-19 jab Turkovac". Anadolu Agency.
- ↑ "Domestic COVID-19 jab Turkovac begins Phase 3 trials in Turkey". Daily Sabah. 22 June 2021. Retrieved 23 June 2021.
- ↑ Clinical trial number NCT04691947 for "Safety and Immunogenicity of Two Different Strengths of the Inactivated COVID-19 Vaccine ERUCOV-VAC (ERUCOV-VAC)" at ClinicalTrials.gov
- ↑ Clinical trial number NCT04824391 for "Efficacy, Immunogenicity and Safety of Inactivated ERUCOV-VAC Compared With Placebo in COVID-19 " at ClinicalTrials.gov
- ↑ "Efficacy, Immunogenicity, and Safety of the Inactivated COVID-19 Vaccine (TURKOVAC) Versus the CoronaVac Vaccine". ClinicalTrials.gov. 28 June 2021. NCT04942405. Retrieved 29 June 2021.
- ↑ "Turkey issues emergency-use authorization for its domestically produced vaccine". NY Times. Retrieved 28 December 2021.
- ↑ "Turkey authorises use of own Turkovac Covid-19 vaccine". France 24. 23 December 2021. Retrieved 24 December 2021.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.